HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eva Dokoupilová Selected Research

PF-06410293

6/2022Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eva Dokoupilová Research Topics

Disease

3Rheumatoid Arthritis
06/2022 - 06/2015
2Injection Site Reaction
12/2020 - 06/2015
1Osteoarthritis
08/2021
1Knee Osteoarthritis
08/2021
1Axial Spondyloarthritis
01/2021
1Nasopharyngitis
06/2015
1Infections
06/2015

Drug/Important Bio-Agent (IBA)

2Biosimilar PharmaceuticalsIBA
06/2022 - 12/2020
1PF-06410293IBA
06/2022
1Adalimumab (Humira)FDA Link
06/2022
1Hyaluronic Acid (Hyaluronan)IBA
08/2021
1Chondroitin Sulfates (Chondroitin Sulfate)IBA
08/2021
1Prostaglandins AIBA
08/2021
1secukinumabIBA
01/2021
1Antirheumatic Agents (DMARD)IBA
12/2020
1Methotrexate (Mexate)FDA LinkGeneric
12/2020
1FletikumabIBA
06/2015
1Monoclonal AntibodiesIBA
06/2015

Therapy/Procedure

2Activities of Daily Living (ADL)
06/2022 - 12/2020
1Injections
08/2021
1Intra-Articular Injections
08/2021